The France Adult Glioma Therapeutics Market is valued at around $61 Mn in 2022 and is projected to reach $111 Mn by 2030, exhibiting a CAGR of 7.9% during the forecast period. The France Adult Malignant Glioma Therapeutics Market is predicted to develop gradually due to glioblastoma's poor prognosis, which drives the need for novel treatments, as well as rising incidence rates that contribute to market expansion. Key players in the France Adult Malignant Glioma Therapeutics Market include companies like Roche, Merck & Co., Novartis, Bayer, Kymab, Cellectis, Lysogene, AbbVie, Bristol-Myers Squibb, and Pfizer among others
Indonesia Clinical Nutrition for Chronic Kidney Diseases Market was valued at $9.40 Mn in 2023 and is predicted to grow at a CAGR of 6.03% from 2023 to 2030, to $14.20 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, technological advancements, and increasing healthcare expenditure. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
The Kenya Herbal Supplements Market was valued at $3.68 Mn in 2023 and is predicted to grow at a CAGR of 7.3% from 2023 to 2030, to $6.03 Mn by 2030. The key drivers of this industry include rising chronic disease, consumer preference for natural products, and increasing health consciousness. The industry is primarily dominated by players such as Himalaya Wellness, Patanjali Ayurved, Dabur, and NOW Foods among others.
Saudi Arabia Brain Cancer Therapeutics Market valued at $39 Mn in 2022, projected to reach $98 Mn by 2030 with a 12.1% CAGR. The market for brain cancer therapeutics is expected to be driven by the anticipated rise in the incidence of brain cancer, especially glioblastoma multiforme, which would raise the demand for therapeutics. The leading pharmaceutical companies presently operating in the industry are Roche, Merck, Novartis, Bristol Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, Teva Pharmaceutical Industries, Sanofi, and Ipsen.
Japan Clinical Nutrition for Chronic Kidney Diseases Market was valued at $97.60 Mn in 2023 and is predicted to grow at a CAGR of 6.53% from 2023 to 2030, to $151.90 Mn by 2030. The key drivers of this industry include the high prevalence of CKD, increasing awareness and education, and technological advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
The South Africa Herbal Supplements Market was valued at $34.19 Mn in 2023 and is predicted to grow at a CAGR of 7.43% from 2023 to 2030, to $56.46 Mn by 2030. The key drivers of this industry include the prevalence of chronic disease, growing health awareness, and a shift towards a healthy lifestyle. The industry is primarily dominated by players such as Himalaya Wellness, Herbalife, NOW Foods, Botanic Supplements, and Dabur among others.
The Japan Brugada Syndrome Market was valued at $74.6 Mn in 2023 and is predicted to grow at a CAGR of 8.3% from 2023 to 2030, to $130.3 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, aging population, and advancements in genetic testing. The prominent players of the Japan Brugada Syndrome Market are Takeda Pharmaceuticals, Astellas, Canon Medical Systems Corporation, Terumo, Nipro, and Otsuka, among others.
The Indonesia Adult Glioma Therapeutics Market is valued at around $13 Mn in 2022 and is projected to reach $26 Mn by 2030, exhibiting a CAGR of 8.9% during the forecast period. The UHC program of the Indonesian government, together with the nation's expanding economic might and a rise in domestic investment and research projects, is greatly boosting the manufacture of generic drugs domestically and encouraging the development of diagnostic and therapeutic technologies. Key players in the Indonesia Adult Malignant Glioma Therapeutics Market include companies like Roche, Novartis, Merck & Co., Pfizer, Bristol-Myers Squibb, Kalbe Farma, Stryker, Elekta, Siemens, etc among others
Singapore Brain Cancer Therapeutics Market valued at $3 Mn in 2022, projected to reach $6 Mn by 2030 with a 11.2% CAGR. Anticipated increases in the occurrence of brain cancer, particularly glioblastoma multiforme, are expected to substantially boost the need for treatments targeting brain cancer, thereby impacting the market's overall landscape. Currently, prominent pharmaceutical entities in the market include Merck & Co, Avatamed, Amgen, Roche, Pfizer, A*STAR, AUM Biosciences, Novartis, AstraZeneca, and Mirati Therapeutics.
Malaysia Clinical Nutrition for Chronic Kidney Diseases Market was valued at $2.50 Mn in 2023 and is predicted to grow at a CAGR of 6.23% from 2023 to 2030, to $3.90 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, increased awareness and education, and technological advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
The India Herbal Supplements Market was valued at $95.66 Mn in 2023 and is predicted to grow at a CAGR of 9.2% from 2023 to 2030, to $177.13 Mn by 2030. The key drivers of this industry include growing health awareness, traditional medicine heritage, and rising incidence of chronic disease. The industry is primarily dominated by players such as Himalaya Wellness, Dabur India, Patanjali Ayurved, Zandu Realty, and Amway among others.
The Malaysia Brugada Syndrome Market was valued at $1.9 Mn in 2023 and is predicted to grow at a CAGR of 8.0% from 2023 to 2030, to $3.3 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, aging population, and increased awareness. The prominent players of the Malaysia Brugada Syndrome Market are Novartis, Amgen, GSK, Merck, Sanofi, and Medtronic, among others.
Canada Blood Disorder Therapeutics Market valued at $1.072 Bn in 2022, projected to reach $1.912 Bn by 2030 with a 7.5% CAGR. The growing adoption of advanced therapies supported by government initiatives, and the rising prevalence of blood disorders, particularly among Canada's aging population, are the main factors driving the market for blood disorder treatment. The Canada Blood Disorder Therapeutics Market encompasses various players across different segments, including Takeda Pharmaceutical, Sanofi, Novo Nordisk, Pfizer, Apotex, Paladin Labs, Sandoz, Spark Therapeutics, Bluebird bio, BioMarin Pharmaceuticals etc, among various others.
Philippines Clinical Nutrition for Chronic Kidney Diseases Market was valued at $3.50 Mn in 2023 and is predicted to grow at a CAGR of 6.53% from 2023 to 2030, to $5.40 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, increased awareness and education, and advancements in nutritional science. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Canada Dental Endodontics Market was valued at $140 Mn in 2023 and is predicted to grow at a CAGR of 4.3% from 2023 to 2030, to $188 Mn by 2030. The key drivers of this industry include the growing demand for cosmetic dentistry, Technological Advancements, the rising prevalence of dental problems, and the aging population. The industry is primarily dominated by Coltene, Dentsply Sirona, FKG Dentaire, and Ultradent Products among others.
The Singapore Brugada Syndrome Market was valued at $1.4 Mn in 2023 and is predicted to grow at a CAGR of 8.4% from 2023 to 2030, to $2.5 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, government fundings, and advancements in genetic testing. The prominent players of the Singapore Brugada Syndrome Market are Bayer, Roche, Siemens Healthineers, Sanofi, Thermo Fisher Scientific, and Novartis, among others.
China Blood Disorder Therapeutics Market valued at $1.077 Bn in 2022, projected to reach $2.145 Bn by 2030 with a 9% CAGR. The key drivers of the China Blood Disorder Therapeutics Market include the growing prevalence of blood illnesses associated with an aging population and industrialization-related factors, coupled with a government push for domestic innovation, increased spending on healthcare, and rising disposable incomes. The China Blood Disorder Therapeutics Market encompasses various players across different segments, including Takeda, Roche, Bayer, Pfizer, Novartis, Johnson & Johnson, BeiGene, Innovent Biologics, Simcere, Shanghai Junshi Biosciences, etc, among various others.
Singapore Clinical Nutrition for Chronic Kidney Diseases Market was valued at $1.90 Mn in 2023 and is predicted to grow at a CAGR of 6.63% from 2023 to 2030, to $3.00 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, increased awareness and education, and advancements in nutritional science. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
US Dental Endodontics Market was valued at $735 Mn in 2023 and is predicted to grow at a CAGR of 2.3% from 2023 to 2030, to $861.8 Mn by 2030. The key drivers of this industry include increasing emphasis on tooth preservation, rising prevalence of dental disease, aging population, and technological advancements. The industry is primarily dominated by Coltene, Dentsply Sirona, FKG Dentaire, and Ultradent Products among others.
The Philippines Brugada Syndrome Market was valued at $2.6 Mn in 2023 and is predicted to grow at a CAGR of 8.3% from 2023 to 2030, to $4.6 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, geriatric population, and advancements in genetic testing. The prominent players of the Philippines Brugada Syndrome Market are Ajanta, Pascual Laboratories, Bauch Laboratories, Uni-Pharma Phils, Roche, and Medtronic, among others.
Egypt Blood Disorder Therapeutics Market valued at $38 Mn in 2022, projected to reach $75 Mn by 2030 with a 9% CAGR. The market is fuelled due to a push from a mix of certain factors like the increased prevalence of Blood Disorders in the country, supported by increased awareness and acceptance and availability of treatment options due to recent technological advancements. The Egypt Blood Disorder Therapeutics Market encompasses various players across different segments, including Takeda, Roche, Novartis, Pfizer, AstraZeneca, Sanofi, Grifols, Octapharma, Pharco Pharmaceuticals, EVA Pharmaceuticals etc, among various others.
Saudi Arabia Dental Endodontics Market was valued at $29.80 Mn in 2023 and is predicted to grow at a CAGR of 5.8% from 2023 to 2030, to $44.10 Mn by 2030. The key drivers of this industry include a growing focus on oral health, the rising prevalence of dental problems, government vision and initiatives, and technological advancements. The industry is primarily dominated by Coltene, Dentsply Sirona, 3M Company, and ZimVie Inc. among others.
The Vietnam Brugada Syndrome Market was valued at $6 Mn in 2023 and is predicted to grow at a CAGR of 10.3% from 2023 to 2030, to $12.2 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, geriatric population, and advancements in genetic testing. The prominent players of the Vietnam Brugada Syndrome Market are Nipro Pharma, Sanofi, StellaPharm, Vimedimex, Medtronic, and GSK, among others.
Brazil Blood Disorder Therapeutics Market valued at $335 Mn in 2022, projected to reach $643 Mn by 2030 with a 8.5% CAGR. Rising prevalence of blood diseases, advanced therapies, and increased healthcare investment are driving the growth of the Brazil Blood Disorder Therapeutics Market. The Brazil market encompasses various players across different segments, including Pfizer, Sanofi, Novartis, Takeda Pharmaceuticals, CSL Behring, Alexion, Eurofarma, Hypera Pharma, Neo Quimica, Cristalia etc, among various others.
Egypt Clinical Nutrition for Chronic Kidney Diseases Market was valued at $4.40 Mn in 2023 and is predicted to grow at a CAGR of 7.53% from 2023 to 2030, to $7.30 Mn by 2030. The key drivers of this industry include rising CKD prevalence, a growing geriatric population, and technological advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.